Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADvance: Phase 3 Study of [18F]PI-2620 PET Imaging for Tau Deposition in Alzheimer's Disease
NCT05641688Phase 3Recruiting
- Sponsor
- Lantheus Holdings, Inc.
- Start
- Dec 2022
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 18F-PI-2620 in Alzheimer's disease (AD), sponsored by Lantheus Holdings, Inc. Primary endpoint: Diagnostic Efficacy of the visual assessment of [18F]PI-2620 PET imaging, in correctly differentiating tau neurofibrillary pathology associated with AD (NFT Score of B0 or B1 = negative) at 1 year. Started Dec 2022; status: recruiting.
02
Drugs
18F-PI-2620
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05641688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05641688.